Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.
Researchers polled people on HIV treatment about their preferences for various forms of long-acting antiretrovirals.
Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.
Periodic infusions of such antibodies may eventually become a new way of treating the virus.
ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.
This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.
Researchers are trying to harness the power of certain antibodies as long-acting injectable forms of HIV treatment or PrEP.
One injection of the cloned antibody significantly reduced participants’ viral load in a recent advanced trial.
HIV-positive members of a recent study saw many upsides to getting injections of meds only every four or eight weeks.
A trial of long-acting cabotegravir injected every eight weeks is already under way among men who have sex with men and trans women.
A recent study tested the long-acting injectable antiretrovirals cabotegravir and Edurant (rilpivirine) given every four or eight weeks.
This is according to a recent survey of gay and bi men taking daily Truvada as PrEP.
Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.
Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.